[{"indications": "Indications\u00a0prevention and treatment of ischaemic neurological deficits following\r\naneurysmal subarachnoid haemorrhage", "name": "NIMODIPINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.2 Calcium-channel blockers"], "cautions": "Cautions\u00a0cerebral oedema or severely raised intracranial pressure; hypotension; avoid concomitant administration of nimodipine tablets and infusion, other calcium-channel blockers, or beta-blockers; concomitant nephrotoxic drugs; interactions: Appendix 1 (calcium-channel blockers, alcohol (infusion only))", "side-effects": "Side-effects\u00a0hypotension, variation in heart-rate, flushing,\r\nheadache, gastro-intestinal disorders, nausea, sweating and feeling\r\nof warmth; thrombocytopenia and ileus reported; overdosage, see Emergency Treatment of Poisoning", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2699.htm", "doses": ["Prevention, by mouth, 60\u00a0mg every 4 hours,\r\nstarting within 4 days of aneurysmal subarachnoid haemorrhage and\r\ncontinued for 21 days", "Treatment, by intravenous infusion via central\r\ncatheter, initially 1\u00a0mg/hour (up to 500\u00a0micrograms/hour if body-weight\r\nless than 70\u00a0kg or if blood pressure unstable), increased after 2\r\nhours to 2\u00a0mg/hour if no severe fall in blood pressure; continue for\r\nat least 5 days (max. 14 days); if surgical intervention during treatment,\r\ncontinue for at least 5 days after surgery; max. total duration of\r\nnimodipine use 21 days"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk"}]